<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158572</url>
  </required_header>
  <id_info>
    <org_study_id>ATI-CL23</org_study_id>
    <nct_id>NCT02158572</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System</brief_title>
  <official_title>A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the efficacy of a contraceptive patch in 2100 healthy women for up to one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AG200-15 is used in a 4-week (28-day) treatment cycle: a patch is applied and replaced every
      7 days for 3 consecutive weeks, followed by a 1-week &quot;patch-free&quot; period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.</measure>
    <time_frame>1 year</time_frame>
    <description>The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, ITT Dataset</measure>
    <time_frame>1 year</time_frame>
    <description>Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI &lt; 30 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, Per-Protocol-Instructions (PPI) Dataset</measure>
    <time_frame>1 year</time_frame>
    <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI Efficacy Dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI , PPI</measure>
    <time_frame>1 year</time_frame>
    <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Self-reported Skin Irritation at Application Site</measure>
    <time_frame>1 year</time_frame>
    <description>Self-reported skin irritation at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported Skin Itching at Application Site</measure>
    <time_frame>1 year</time_frame>
    <description>Self-reported skin itching at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported Patch Adhesion</measure>
    <time_frame>1 year</time_frame>
    <description>Patch adhesion was reported using the following 5-point scoring method:
0: ≥ 90% adhered (none to minimal lift)
≥ 75% adhered but &lt; 90% (some edges showing lift)
≥ 50% adhered but &lt; 75% (at least half of system lifts off)
&lt; 50% (more than half of the patch lifts off, but the patch remains attached)
Patch completely detached.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cycle Control</measure>
    <time_frame>1 year</time_frame>
    <description>Number of episodes of breakthrough bleeding (BTB) and/or breakthrough spotting (BTS) per cycle.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2032</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AG200-15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG200-15</intervention_name>
    <description>Transdermal contraceptive delivery system</description>
    <arm_group_label>AG200-15</arm_group_label>
    <other_name>Transdermal contraceptive delivery system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, sexually active woman at risk for pregnancy seeking to use hormonal
             contraception for at least 1 year

          -  Ability to demonstrate willingness to participate and adhere to study protocol

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Lactating women

          -  Anticipates use of condoms or any other form of back-up contraception during the study

          -  History of dermal sensitivity to medicated patches (nicotine) or to bandages, surgical
             tape, etc.

          -  Has a contraindication to combined estrogen-progestin contraceptive use

          -  Any disease that may worsen under hormonal treatment (cardiovascular, liver,
             metabolic)

          -  Smoker who is 35 years old or over
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Garner, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Agile Therapeutics</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <results_first_submitted>July 25, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2017</results_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention of pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AG200-15</title>
          <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2032"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="989"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1043"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>AG200-15</title>
          <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2031"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2031"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2031"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.</title>
        <description>The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population: all complete or incomplete on-therapy cycles in which intercourse occurred and no back-up contraception was used.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset.</title>
          <description>The Pearl Index will serve as the primary contraceptive efficacy endpoint for evaluation of pregnancy rates for the study. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
          <population>ITT population: all complete or incomplete on-therapy cycles in which intercourse occurred and no back-up contraception was used.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1736"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.55" upper_limit="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, ITT Dataset</title>
        <description>Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI &lt; 30 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
        <time_frame>1 year</time_frame>
        <population>ITT population: all complete or incomplete on-therapy cycles in which intercourse occurred and no back-up contraception was used.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, ITT Dataset</title>
          <description>Contraception efficacy of AG200-15 by Pearl Index in subjects ≤ 35 years of age with BMI &lt; 30 kg/m2, ITT dataset. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.</description>
          <population>ITT population: all complete or incomplete on-therapy cycles in which intercourse occurred and no back-up contraception was used.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" lower_limit="2.53" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, Per-Protocol-Instructions (PPI) Dataset</title>
        <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI Efficacy Dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
        <time_frame>1 year</time_frame>
        <population>PPI population</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age With BMI &lt; 30 kg/m2, Per-Protocol-Instructions (PPI) Dataset</title>
          <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI Efficacy Dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
          <population>PPI population</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.66" lower_limit="2.25" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI , PPI</title>
        <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
        <time_frame>1 year</time_frame>
        <population>PPI population</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI , PPI</title>
          <description>Contraception efficacy measured by Pearl Index. Pearl Index is the number of on-therapy pregnancies times 1300 divided by the number of 28-day on-therapy cycles and is an estimate of the number of pregnancies per 100 woman-years of product use.
PPI dataset: All complete or incomplete on-therapy cycles in which intercourse occurred, excluding the following two cohorts of cycles.
Cohort 1: cycles in which a back-up method of contraception was used for reasons other than the protocol-specified procedures for missed days of patch use, unless pregnancy occurred; and Cohort 2: cycles in which the subject missed ≥ 1 day of patch use and did not adhere to the recommended procedures for missed days of patch use.)</description>
          <population>PPI population</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1714"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="3.25" upper_limit="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Skin Irritation at Application Site</title>
        <description>Self-reported skin irritation at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
        <time_frame>1 year</time_frame>
        <population>Subjects who reported irritation at the application site.</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Skin Irritation at Application Site</title>
          <description>Self-reported skin irritation at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
          <population>Subjects who reported irritation at the application site.</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Skin Itching at Application Site</title>
        <description>Self-reported skin itching at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
        <time_frame>1 year</time_frame>
        <population>Subjects who reported itching at the application site</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Skin Itching at Application Site</title>
          <description>Self-reported skin itching at application site was assessed using the following scoring method:
0: None
Mild
Moderate
Severe</description>
          <population>Subjects who reported itching at the application site</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Self-reported Patch Adhesion</title>
        <description>Patch adhesion was reported using the following 5-point scoring method:
0: ≥ 90% adhered (none to minimal lift)
≥ 75% adhered but &lt; 90% (some edges showing lift)
≥ 50% adhered but &lt; 75% (at least half of system lifts off)
&lt; 50% (more than half of the patch lifts off, but the patch remains attached)
Patch completely detached.</description>
        <time_frame>1 year</time_frame>
        <population>Subjects that reported patch adhesion</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported Patch Adhesion</title>
          <description>Patch adhesion was reported using the following 5-point scoring method:
0: ≥ 90% adhered (none to minimal lift)
≥ 75% adhered but &lt; 90% (some edges showing lift)
≥ 50% adhered but &lt; 75% (at least half of system lifts off)
&lt; 50% (more than half of the patch lifts off, but the patch remains attached)
Patch completely detached.</description>
          <population>Subjects that reported patch adhesion</population>
          <units>Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2022"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="1.518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cycle Control</title>
        <description>Number of episodes of breakthrough bleeding (BTB) and/or breakthrough spotting (BTS) per cycle.</description>
        <time_frame>1 year</time_frame>
        <population>Subjects that reported BTB and/or BTS</population>
        <group_list>
          <group group_id="O1">
            <title>AG200-15</title>
            <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Cycle Control</title>
          <description>Number of episodes of breakthrough bleeding (BTB) and/or breakthrough spotting (BTS) per cycle.</description>
          <population>Subjects that reported BTB and/or BTS</population>
          <units>Episodes/cycle</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2017"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AG200-15</title>
          <description>AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
AG200-15: Transdermal contraceptive delivery system</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phenylketonuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Gastric fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiorgan failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Heptitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Small Intestine Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papillary thryriod cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Substance Abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Oliguira</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Acute repiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="627" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="116" subjects_affected="116" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="100" subjects_affected="100" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="2031"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="2031"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Approval by Agile Therapeutics, Inc. of any publication, including oral presentations and abstracts, utilizing data or any information from the ATI-CL23 study is required prior to publication submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Flood, Associate Director of Clinical Operations</name_or_title>
      <organization>Agile Therapeutics</organization>
      <phone>609-683-1880</phone>
      <email>lflood@agiletherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

